Results 91 to 100 of about 47,826 (189)
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.ABSTRACT The accelerated development of innovative anticancer therapies has led to the early approval of an increasing number of drugs. However, clinical evidence available at the time of approval is often limited, necessitating additional post‐marketing studies to supplement safety and efficacy data.
Aina Tsuno, Hiroe Kitagaki, Hideki Maeda
wiley +1 more source
Use of capecitabine in management of early colon cancer
Cancer Management and Research, 2011 H Hameed, J CassidyBeatson West of Scotland Cancer Centre, Glasgow, Scotland, UKAbstract: Capecitabine (Xeloda®, Roche, Basel, Switzerland) is a pro-drug of 5-fluorouracil (5-FU), and it is converted to 5-FU in the cancer cell by enzymatic ...
Cassidy J, Hameed H
doaj
Redefining the Role of Chemotherapy and Targeted Cytotoxic Delivery in Lung Neuroendocrine Tumors
Thoracic Cancer, Volume 17, Issue 16, August 2026.Perioperative chemotherapy utility remains uncertain and lacks universal standardization. Platinum/etoposide shows suboptimal efficacy in lung NET (neuroendocrine tumors); oral alkylators (temozolomide) alone or in combination (e.g., with capecitabine), and cabozantinib offer promising disease control.
Alice Laffi +2 more
wiley +1 more source
Application of Systems Genetics to Investigate Molecular Pathology of Early‐Onset Colorectal Cancer
Chemical Biology &Drug Design, Volume 108, Issue 2, August 2026.Early‐onset colorectal cancer (EOCRC) presents a complex molecular landscape that requires integrated multi‐omics approaches. This article reviews current applications of systems genetics in EOCRC research and provides a step‐by‐step protocol for network‐based analyses featuring PIK3CA to demonstrate practical application for researchers of all levels.
Minjae J. Kim +3 more
wiley +1 more source
Prognostic impact of time from diagnosis to start of radiotherapy in anal cancer
Colorectal Disease, Volume 28, Issue 8, August 2026.Abstract Aim A prolonged time from diagnosis to start of radiotherapy (TTRT) for malignant disease may negatively influence survival, but studies in squamous cell carcinoma of the anus (SCCA) are largely lacking. The purpose of this study was to investigate the impact of TTRT on overall survival (OS) and anal cancer‐specific survival (ACSS) in a ...
Jakob Hallström +2 more
wiley +1 more source
Tutorial on Analyzing Patient‐Reported Outcome Measures in Clinical Development
Clinical and Translational Science, Volume 19, Issue 8, August 2026.ABSTRACT Patient‐reported outcomes (PROs) are now considered essential components of clinical development and regulatory assessment. Despite their widespread collection, PRO data remain under‐utilized, with analyses often limited to descriptive summaries or single time‐point comparisons that fail to capture the richness, longitudinal structure, and ...
Krina Mehta +4 more
wiley +1 more source
Clinical and Translational Science, Volume 19, Issue 8, August 2026.ABSTRACT Omics biomarkers comprise several molecular entities, including genomic, epigenomic, transcriptomic, proteomic, and metabolomic signatures. They play an essential role in oncology drug development and clinical settings by enabling personalized medicine.
Mai Mehanna +8 more
wiley +1 more source
Can acromegaly be controlled in all cases?
Journal of Neuroendocrinology, Volume 38, Issue 8, August 2026.Abstract Acromegaly is a rare disease, due in most of the cases to a growth hormone (GH)‐secreting pituitary adenoma (PA), namely neuroendocrine tumour (PitNET). The treatment of patients with acromegaly is multimodal and multi‐step, including surgery, medical therapies, and radiotherapy.
Sabrina Chiloiro +14 more
wiley +1 more source
Pancreatic Cancer—Advances in the Last 50 Years
World Journal of Surgery, Volume 50, Issue 8, Page 2106-2115, August 2026.
S. George Barreto +5 more
wiley +1 more source